AAPG Ascentage Pharma Group International - American Depository Shares
$19.00
Price · Aug 14, 2026
52W Range
$16–$48
8% of range
Analyst Rating
BUY
11 analysts
Price Target
$48
+150% upside
P/E (TTM)
—
ROE
—
Net Profit Margin
—
AAPG Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$19.00
Market Cap
—
P/E (TTM)
—
EPS (TTM)
—
Revenue (TTM)
—
Div Yield
—
ROE
—
Debt/Equity
—
52W Range
$16 – $48
AAPG Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
—
EPS
—
Free Cash Flow
—
Margins
—
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
AAPG
Peer Median
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
AAPG
Peer Median
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
AAPG
Peer Median
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
AAPG
Peer Median
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
AAPG
Peer Median
AAPG Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
BUY
11 analysts
- Strong Buy 4 36.4%
- Buy 6 54.5%
- Hold 1 9.1%
- Sell 0 0.0%
- Strong Sell 0 0.0%
12-Month Price Target
9 analysts · 2026-08-13
Median
$48.00
← Below all targets
$19.00
Low
$40.00
High
$55.00
Median target
$48.00
+152.6%
Mean target
$47.56
+150.3%
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Institutional owners (13F) 9 filers · $958K total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 3 (+3 vs prior Q) | 2 (-3 vs prior Q) | 1 (-1 vs prior Q) | 2 (-1 vs prior Q) | -15K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| Point72 (DIFC) Ltd | $699,987 | 17,930 | 73.06% | Shares |
| Point72 Asset Management, L.P. | $243,048 | 13,841 | 25.37% | Shares |
| MORGAN STANLEY | $10,747 | 612 | 1.12% | Shares |
| WELLS FARGO & COMPANY/MN | $3,512 | 200 | 0.37% | Shares |
| EverSource Wealth Advisors, LLC | $421 | 24 | 0.04% | Shares |
| UBS Group AG | $263 | 15 | 0.03% | Shares |
| BlackRock, Inc. | $105 | 6 | 0.01% | Shares |
| Caitong International Asset Management Co., Ltd | $18 | 1 | 0.00% | Shares |
| ROYAL BANK OF CANADA | $0 | 6 | 0.00% | Shares |
Company insiders 3 insiders · 3 officers · 1 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Dajun Yang | Chairman and CEO | May 21, 2026 M | 405,280 | 0 | 0 | $0 |
| Veet Misra | Chief Financial Officer | April 20, 2026 A | — | 0 | 0 | $0 |
| Yifan Zhai | Chief Medical Officer | May 20, 2026 A | 1,193,569 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only